Hyloris' Alenura meets primary endpoint in Phase 2 bladder pain trial

• Hyloris and Vaneltix today reported positive Phase 2 results for Alenura in acute bladder pain associated with interstitial cystitis/bladder pain syndrome.
• The trial met its primary goal, showing superior pain relief versus placebo and either active ingredient alone.
• The findings support preparations for a US marketing application, subject to remaining clinical and regulatory requirements.
• An estimated six million or more Americans experience symptoms consistent with the condition; no FDA-approved treatment specifically targets its acute bladder pain.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hyloris Developments SA published the original content used to generate this news brief on November 08, 2026, and is solely responsible for the information contained therein.